IL151791A0 - Pharmaceutical composition for the treatment of respiratory diseases - Google Patents

Pharmaceutical composition for the treatment of respiratory diseases

Info

Publication number
IL151791A0
IL151791A0 IL15179101A IL15179101A IL151791A0 IL 151791 A0 IL151791 A0 IL 151791A0 IL 15179101 A IL15179101 A IL 15179101A IL 15179101 A IL15179101 A IL 15179101A IL 151791 A0 IL151791 A0 IL 151791A0
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical composition
respiratory diseases
glycopyrrolate
dry powder
Prior art date
Application number
IL15179101A
Other languages
English (en)
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151791(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of IL151791A0 publication Critical patent/IL151791A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
IL15179101A 2000-04-07 2001-04-09 Pharmaceutical composition for the treatment of respiratory diseases IL151791A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
IL151791A0 true IL151791A0 (en) 2003-04-10

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15179101A IL151791A0 (en) 2000-04-07 2001-04-09 Pharmaceutical composition for the treatment of respiratory diseases
IL151791A IL151791A (en) 2000-04-07 2002-09-18 Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151791A IL151791A (en) 2000-04-07 2002-09-18 Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases

Country Status (25)

Country Link
US (3) US7229607B2 (de)
EP (3) EP1449528B1 (de)
JP (1) JP5042426B2 (de)
CN (3) CN1292745C (de)
AT (1) ATE330585T2 (de)
AU (2) AU2004242450B2 (de)
BE (1) BE2013C023I2 (de)
BR (1) BR0109875A (de)
CA (1) CA2405705C (de)
CY (1) CY1105120T1 (de)
DE (1) DE60120936T3 (de)
DK (1) DK1267866T4 (de)
ES (2) ES2687751T3 (de)
GB (1) GB0008660D0 (de)
HK (1) HK1050846B (de)
HU (2) HU230958B1 (de)
IL (2) IL151791A0 (de)
LU (2) LU92166I2 (de)
MX (1) MXPA02009718A (de)
NO (3) NO336142B1 (de)
NZ (2) NZ521476A (de)
PL (1) PL364024A1 (de)
PT (1) PT1267866E (de)
WO (1) WO2001076575A2 (de)
ZA (1) ZA200207420B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP1337239B2 (de) 2000-11-30 2015-11-25 Vectura Limited Partikel zur verwendung in einer pharmazeutischen zusammensetzung
PT1920763E (pt) 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
JP4510384B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
PT3536344T (pt) * 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ES2375706T3 (es) * 2003-11-14 2012-03-05 Baxter International Inc. Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
CN101518532A (zh) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
EP1718336B1 (de) * 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
EP1720577A2 (de) * 2004-02-27 2006-11-15 Altana Pharma AG Kombination aus ciclesonid und glycopyrronium
JP2007528409A (ja) * 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1763344A1 (de) * 2004-06-29 2007-03-21 Boehringer Ingelheim International GmbH Medikamente zur inhalation mit steroiden und einem anticholinergikum
EP1616567A1 (de) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medikamente enthaltend PDE-IV Hemmer und Glycopyrrolatsalzen zur Inhalation
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
MX2007011273A (es) 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
WO2007071313A2 (en) * 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
PL2234595T3 (pl) * 2007-12-13 2013-04-30 Novartis Ag Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania
AU2008334547B2 (en) * 2007-12-13 2011-06-30 Novartis Ag Organic compounds
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PL3111926T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
EP2515855B3 (de) 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Kombinationstherapie für COPD
KR20120106753A (ko) 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
IL286573B (en) 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20140294969A1 (en) 2011-08-01 2014-10-02 Monash University Method and formulation for inhalation
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
EP3082708B1 (de) * 2013-12-17 2019-04-03 Merck Sharp & Dohme Corp. Medienmahlverfahren zur herstellung von pharmazeutischen wirkstoffen in treibmitteln
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
JP6502501B2 (ja) 2014-09-09 2019-04-17 ベクトゥラ・リミテッド グリコピロレートを含む製剤、方法、及び装置
ES2670025T3 (es) * 2014-09-15 2018-05-29 Verona Pharma Plc Formulación para inhalación líquida que comprende RPL554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
EP3307250B1 (de) * 2015-06-15 2022-11-23 QAAM Pharmaceuticals, LLC Glycopyrroniumfettsäuresalze und verfahren zur herstellung
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
KR20220108047A (ko) 2019-12-02 2022-08-02 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
AU745331B2 (en) 1996-11-11 2002-03-21 Meda Pharma Gmbh & Co. Kg Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2236832T3 (es) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 Henkel IP & Holding GmbH 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
EP1267866B2 (de) 2016-07-20
NO2015025I1 (no) 2015-12-07
DK1267866T3 (da) 2006-10-23
AU8930601A (en) 2001-10-23
NO2015024I1 (no) 2015-11-25
WO2001076575A3 (en) 2002-03-28
CA2405705C (en) 2011-06-07
BE2013C023I2 (de) 2020-06-24
NO336142B1 (no) 2015-05-26
US20030068280A1 (en) 2003-04-10
HUS1900056I1 (hu) 2020-02-28
NO20024708D0 (no) 2002-10-01
EP2193791A1 (de) 2010-06-09
NZ521476A (en) 2004-10-29
CA2405705A1 (en) 2001-10-18
ATE330585T2 (de) 2006-07-15
WO2001076575A2 (en) 2001-10-18
AU2010200660B2 (en) 2012-04-19
CN101181263B (zh) 2011-07-06
AU776913B2 (en) 2004-09-23
US7229607B2 (en) 2007-06-12
CN1720995A (zh) 2006-01-18
AU2004242450A1 (en) 2005-01-20
LU92166I2 (fr) 2014-03-13
DE60120936D1 (de) 2006-08-03
DE60120936T3 (de) 2016-11-17
GB0008660D0 (en) 2000-05-31
CN1292745C (zh) 2007-01-03
HK1050846A1 (en) 2003-07-11
HUP0301518A2 (hu) 2003-08-28
HK1050846B (zh) 2007-01-26
AU2010200660A1 (en) 2010-03-11
EP1267866A2 (de) 2003-01-02
NZ535284A (en) 2006-04-28
ES2266242T3 (es) 2007-03-01
JP5042426B2 (ja) 2012-10-03
DK1267866T4 (en) 2016-10-03
MXPA02009718A (es) 2003-05-27
PL364024A1 (en) 2004-11-29
US20080220073A1 (en) 2008-09-11
ZA200207420B (en) 2003-09-16
EP1449528A1 (de) 2004-08-25
BR0109875A (pt) 2004-07-20
EP1267866B1 (de) 2006-06-21
PT1267866E (pt) 2006-10-31
LU92393I2 (fr) 2015-11-02
CN101181263A (zh) 2008-05-21
US7368104B2 (en) 2008-05-06
US20050019271A1 (en) 2005-01-27
ES2687751T3 (es) 2018-10-29
CY1105120T1 (el) 2010-03-03
CN1422154A (zh) 2003-06-04
DE60120936T2 (de) 2006-11-02
AU2004242450B2 (en) 2010-06-03
JP2003530344A (ja) 2003-10-14
NO2015024I2 (no) 2015-11-25
EP1449528B1 (de) 2018-08-08
HU230958B1 (hu) 2019-06-28
US8029768B2 (en) 2011-10-04
IL151791A (en) 2015-05-31
ES2266242T5 (es) 2016-10-04
NO20024708L (no) 2002-10-24

Similar Documents

Publication Publication Date Title
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
MXPA02011311A (es) Composicion novedosa.
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
CA2389349A1 (en) Aerosol composition comprising formoterol
DE60318193D1 (en) Phenethanolaminderivate
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2004037807A3 (en) Medicinal arylethanolamine compounds
IL152532A0 (en) Pharmaceutical compositions comprising micronised formoterol and process for their preparation
TW200612909A (en) Compounds
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
MXPA04007294A (es) Composicion para inhalacion.
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
IL165574A0 (en) Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion

Legal Events

Date Code Title Description
EXTE Period for filing application for extension order has been extended (section 64p.(4))